Vivani Medical (NASDAQ:VANI) Given “Buy” Rating at HC Wainwright

Vivani Medical (NASDAQ:VANI)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $4.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 284.62% from the stock’s previous close.

Vivani Medical Stock Down 1.0 %

Shares of VANI stock opened at $1.04 on Thursday. The company has a market cap of $61.60 million, a P/E ratio of -2.31 and a beta of 3.20. Vivani Medical has a twelve month low of $1.03 and a twelve month high of $2.22. The business has a fifty day simple moving average of $1.17 and a 200 day simple moving average of $1.23.

Institutional Trading of Vivani Medical

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC bought a new stake in Vivani Medical during the 4th quarter worth $66,000. Wealthedge Investment Advisors LLC acquired a new position in shares of Vivani Medical in the fourth quarter valued at approximately $43,000. Geode Capital Management LLC raised its holdings in Vivani Medical by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 342,891 shares of the company’s stock valued at $401,000 after buying an additional 15,008 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Vivani Medical by 19.1% during the 4th quarter. Northern Trust Corp now owns 71,915 shares of the company’s stock worth $83,000 after buying an additional 11,540 shares during the period. Institutional investors own 6.78% of the company’s stock.

About Vivani Medical

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.